The EPS miss vs. consensus (-$0.19 actual vs. -$0.41 estimate) is a beat in absolute terms but a miss on the estimate — the stock may not react strongly given the small absolute numbers. Key catalyst is FDA feedback in Q4 2026 on the new brilaroxazine formulation; any positive news could drive a rally, but the company needs additional financing to start the RECOVER-2 trial. Monitor cash burn rate and any partnership announcements.
Price Chart
Executive Summary
Reviva Pharmaceuticals reported Q2 2026 net loss of $2.4M ($0.19/share), narrower than the $6.1M loss in Q2 2025, but EPS of -$0.19 missed the consensus estimate of -$0.41 by 53.7% (a beat on a per-share basis vs. the estimate, though the absolute loss was lower). The company highlighted a new brilaroxazine patent application and expects FDA feedback in Q4 2026 on using a new formulation in its RECOVER-2 Phase 3 trial, with patient enrollment now pushed to 1H 2027 subject to additional financing. Cash increased to $19.9M from $14.4M at year-end 2025, but the stock's historical performance on prior reports shows a -28.5% average T+20 return and only 38% win rate, suggesting limited market conviction in near-term catalysts.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $2.4M ($0.19/share) vs. $6.1M ($2.40/share) in Q2 2025 — loss narrowed significantly on a per-share basis due to reverse stock split and share count increase.
- EPS of -$0.19 missed consensus estimate of -$0.41 by 53.7% (the actual loss per share was smaller than the estimate, but the 'miss' reflects the estimate being more negative).
- Cash and cash equivalents $19.9M as of June 30, 2026, up from $14.4M at Dec 31, 2025.
- Filed U.S. composition of matter patent application for a new form of brilaroxazine, seeking to extend patent life through 2046.
- FDA feedback on use of new brilaroxazine formulation in RECOVER-2 trial and NDA expected Q4 2026.
- Patient enrollment in RECOVER-2 Phase 3 trial expected to initiate in 1H 2027, subject to additional financing.
- Bioequivalence study expected to initiate in Q4 2026.
- Historical performance on prior RVPH reports shows average T+20 return of -28.5% and 38% win rate, indicating low market conviction.
Financial Impact
Net loss narrowed from $6.1M to $2.4M YoY; cash burn reduced; no revenue reported.
Risk Factors
- Dependence on additional financing to initiate RECOVER-2 trial — cash runway may be limited.
- FDA feedback in Q4 2026 is binary; negative feedback could delay program significantly.
- OTCQB listing with limited liquidity and high volatility.
- Historical poor performance of prior reports suggests market skepticism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Press Release | $0.3521 $0.3521 | · 0.00% | ▲ +1.75% | $0.5000 (+42.01%) |
Jul 10, 2026 12w ago | 25-NSE | $0.6200 $0.4775 | ▲ +22.98% | ▲ +25.40% | $0.5000 (+19.35%) |
May 13, 2026 20w ago | Press Release | $0.3900 $0.6839 | ▼ −75.36% | ▼ −76.22% | $0.5000 (−28.21%) |
May 13, 2026 20w ago | 8-K | $0.3521 $0.7600 | ▼ −115.85% | ▼ −116.46% | $0.5000 (−42.01%) |
Apr 15, 2026 24w ago | 8-K | $0.8900 $0.8000 | ▼ −10.11% | ▼ −16.16% | $0.5000 (−43.82%) |
Mar 30, 2026 26w ago | Press Release | $0.6600 $0.8800 | ▲ +33.33% | ▲ +20.74% | $0.5000 (−24.24%) |
Mar 19, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▼ −2.41% | ▲ +5.21% | $0.5000 (+39.76%) |
Mar 18, 2026 28w ago | Press Release | $0.8300 $0.8500 | ▲ +2.41% | ▼ −5.21% | $0.5000 (−39.76%) |
Mar 5, 2026 30w ago | 8-K | $4.20 $0.7200 | ▼ −82.86% | ▼ −79.07% | $0.5000 (−88.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access